Table of contents


Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in November 2015 at the end of the period of market exclusivity.

On 12 December 2003, orphan designation (EU/3/03/178) was granted by the European Commission to Pfizer Limited, United Kingdom, for sildenafil citrate for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Sildenafil citrate has been authorised in the EU as Revatio since 28 October 2005.

Key facts

Active substance
sildenafil citrate
Medicine name
Disease / condition
Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Date of first decision
EU designation number

Sponsor's contact details

Pfizer Limited
Ramsgate Road
Kent CT13 9NJ
United Kingdom
Tel. +44 (0)1304 616 161
Fax +44 (0)1304 652 144

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating